Glenmark launches generic of Inlyta tablets for kidney cancer treatment in US
Glenmark Pharmaceuticals Inc has announced the launch of Axitinib Tablets in the United States in two strengths. These tablets are a generic version of Pfizer's Inlyta, used for advanced renal cell carcinoma treatment. The introduction of this pro...
Glenmark Axitinib tablets (a generic equivalent to Pfizer's Inlyta) are used to treat advanced renal cell carcinoma (RCC), a type of kidney cancer.
"The launch of Axitinib tablets reinforces Glenmark's commitment to expanding access to quality, affordable medicines for patients in the United States," said Marc Kikuchi, President & Business Head, North America.
By adding this product to its portfolio, the company continues to strengthen focus on addressing the evolving needs of patients and healthcare providers, he said .
According to IQVIA sales data for the 12-month period ended September 2026, annual sales of Inlyta tablets in the US were around USD 538.4 million, the company said in a statement.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.